An Illinois resident filed a Xarelto lawsuit against Janssen Pharmaceuticals and Bayer Healthcare Pharmaceuticals after allegedly experiencing severe bleeding and other injuries that required hospitalization.

Plaintiff Dr. Richard S. and his wife Leroya S. filed the Xarelto lawsuit together, with Leroya alleging loss of consortium as a result of her husband’s injuries. 

The plaintiff was prescribed Xarelto in July 2014 to treat chronic atrial fibrillation. He stopped using the medication on Aug. 17, 2014 when he suffered “a serious internal bleeding event requiring multiple days of hospitalization” as an alleged result of taking Xarelto, according to the Xarelto uncontrollable bleeding lawsuit.

In addition to the severe internal bleeding, the plaintiff allegedly experienced loss of blood pressure in the brain which resulted in loss of motor skills, mental acuity, and the ability to speak. These and other injuries caused pain and required extensive medical expenses.

Xarelto Dangers

Xarelto (rivaroxaban) is a medication used to reduce the risk of stroke and systemic embolism as well as to treat deep vein thrombosis and pulmonary embolism. It is also used to prevent blood clots in patients who are undergoing hip replacement or knee replacement surgery.

Xarelto was approved by the U.S. Food and Drug Administration in 2011 and was promoted as an alternative to warfarin, requiring less monitoring. However, there is no antidote to Xarelto should bleeding complications occur, while there is one for warfarin.

The Xarelto lawsuit states that Janssen and Bayer “overstated the efficacy of Xarelto” in regards to what it was supposed to do and “failed to adequately disclose” the lack of antidote. The drug makers also allegedly failed to warn against the potential “permanently disabling, life-threatening and fatal consequences.”

Janssen allegedly misrepresented the safety risks associated with Xarelto to the medical community and the FDA in order to increase Xarelto profits. The drug makers were also accused of failing to run sufficient tests during clinical trials.

On June 6, 2013, the FDA required the defendants to stop promoting Xarelto as they had in the past because they found the material to be “false or misleading,” according to the FDA letter. While the promotions ceased, Xarelto use and perception allegedly failed to change.

Hundreds of Xarelto side effect adverse event reports have been filed with the FDA, including numerous deaths. In 2012 alone, 233 deaths were reported to the FDA.

Xarelto Uncontrollable Bleeding Lawsuit

Richard and Leroya are seeking compensatory damages due to the dangerous bleeding, pain and mental anguish, diminished enjoyment of life, medical treatment, follow-up care, and medication that allegedly followed Richard’s Xarelto use.

The Xarelto uncontrollable bleeding lawsuit charge the defendants with negligence, product liability, breach of warranty, fraudulent misrepresentation and concealment, negligent misrepresentation, fraud and deceit, and loss of consortium.

Many individuals have filed Xarelto lawsuits claiming that the blood thinning medication caused them to develop uncontrollable internal bleeding, deep vein thrombosis, or other dangerous conditions. A Xarelto side effects class action lawsuit investigation is currently underway.

This Xarelto Uncontrollable Bleeding Lawsuit is Case No. 3:13-cv-01332, in the U.S. District Court for the Southern District of Illinois.